Glucose sensing (eg. glucokinase activity) becomes impaired in the development of type 2 diabetes, the etiology of which is unclear. Estrogen can stimulate glucokinase activity, whereas the pervasive environmental pollutant bisphenol A (BPA) can inhibit estrogen action, hence we aimed to determine the effect of BPA on glucokinase activity directly.
To evaluate a potential acute effect on hepatic glucokinase activity, BPA in water (n = 5) vs. water alone (n = 5) was administered at the EPA’s purported “safe dose” (50 µg/kg) by gavage to lean 6-month old male C57BL/6 mice. Two hours later, animals were euthanized and hepatic glucokinase activity measured over glucose levels from 1–20 mmol/l in liver homogenate. To determine the effect of chronic BPA exposure on hepatic glucokinase activity, lean 6-month old male C57BL/6 mice were provided with water (n = 15) or water with 1.75 mM BPA (~50 µg/kg/day; n = 14) for 2 weeks. Following the 2-week exposure, animals were euthanized and glucokinase activity measured as above.
Hepatic glucokinase activity was signficantly suppressed after 2 hours in animals given an oral BPA bolus compared to those who received only water (p = 0.002–0.029 at glucose 5–20 mmol/l; overall treatment effect p<0.001). Exposure to BPA over 2 weeks also suppressed hepatic glucokinase activity in exposed vs. unexposed mice (overall treatment effect, p = 0.003). In both experiments, the Hill coefficient was higher and Vmax lower in mice treated with BPA.
Both acute and chronic exposure to BPA significantly impair hepatic glucokinase activity and function. These findings identify a potential mechanism for how BPA may increase risk for diabetes.
Citation: Perreault L, McCurdy C, Kerege AA, Houck J, Færch K, et al. (2013) Bisphenol A Impairs Hepatic Glucose Sensing in C57BL/6 Male Mice. PLoS ONE 8(7): e69991. doi:10.1371/journal.pone.0069991
Editor: Angel Nadal, Universidad Miguel Hernández de Elche, Spain
Received: April 2, 2013; Accepted: June 18, 2013; Published: July 29, 2013
Copyright: © 2013 Perreault et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding was provided by American Diabetes Association (1-09-CD-11). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Weight loss and exercise remain the cornerstones of diabetes prevention. Nevertheless, the paradigm that dietary over-consumption and physical inactivity are the single determinants of weight gain and diabetes risk has recently been challenged as overly simplistic. In 2002, Baillie-Hamilton postulated a role for chemical toxins in the etiology of obesity by showing that the obesity epidemic coincided with the marked increase of industrial chemicals in the environment over the past 40 years . The global hypothesis put forth by Baillie-Hamilton was that environmental toxins contribute to obesity through dysregulated feeding behavior. To date, this hypothesis is unproven, but has sparked considerable interest in the role of pesticides, organic pollutants and environmental toxins in human health and disease. Indeed, a recently published post hoc analysis from the 2003–2004 U.S. National Health and Nutrition Examination Survey (NHANES) showed a 39% increase in incident type 2 diabetes for every 1 standard deviation increase in urinary concentration of the environmental toxin, bisphenol A (BPA) . Importantly, the 4 other phenols measured did not correlate with diabetes incidence or any other disease. The authors concluded that BPA conferred particular risk for diabetes which is especially concerning given the widespread human exposure.
Proposed mechanisms linking BPA to the development of diabetes are numerous and include fetal programming , sex steroid imbalance , altered adipocyte biology , disrupted beta cell function  and oxidative stress . Nevertheless, because BPA is hepatically metabolized, its toxicity in the liver appears particularly prominent . Further, there is reason to speculate that BPA may be an environmental inhibitor of hepatic glucokinase, specifically. Glucokinase has been definitively shown as the body’s glucose sensor in beta cells, enteroendocrine cells of the gut, hypothalamus and liver. Retinoic acid , , biotin , , and sorbitol  have all been shown to alter the transcription, translation, or activity of glucokinase, but none of these factors have changed much in the American diet over the past 30 years, making them unlikely candidates as dietary regulators of diabetes risk. In contrast, BPA – new to the American diet over the past 40 or so years – is also known as an “endocrine disruptor” due its estrogenic effects , –. The latter is of particular interest as estrogen action may be antagonized, not synergized, by BPA specifically in the liver – where glucokinase has a key glucoregulatory role. Despite the known actions of estrogen on glucokinase, and of BPA on estrogen action, no study to date had examined BPA’s effect on glucokinase, hence was the aim of the current investigation.
All animal studies were approved by the Institutional Animal Care and Use Committee at the University of Colorado School of Medicine. All studies were conducted in lean male C57BL/6 mice 6 months of age.
Acute BPA exposure.
To determine the acute effect on hepatic glucokinase activity, BPA in water (n = 5) vs. water alone (n = 5) was administered at the Environmental Protection Agency’s (EPA) purported “safe dose” (50 µg/kg) by gavage. Two hours later, animals were anesthetized with isoflurane and euthanized by cervical dislocation. Livers were rapidly dissected, weighed and immediately homogenized for the measurement of hepatic glucokinase activity.
Chronic BPA exposure.
To determine the chronic effect of BPA on hepatic glucokinase activity, mice were provided ad libitum access to water without (n = 15) or water with 1.75 mM BPA in glass bottles which resulted in an estimated dose of ~50 µg/kg/day for 2 weeks (n = 14). BPA concentration was measured in the urine of the animals at day 14 to confirm exposure. Animals were euthanized at day 14, livers collected and glucokinase activity measured, as described below.
Hepatic glucokinase activity.
Hepatic glucokinase (hexokinase IV) activity was determined in whole liver homogenate using a colorimetric assay (absorbance at 340 nm for 20 minutes; BioTek Synergy H1 hybrid reader, using Gen5 v2.00 software). Livers were weighed and homogenized for 1 minute using a Kinble Contes glass homogenizer in a buffer containing 100 mM Tris HCl, then adjusted to a final 10X dilution. Ten µl of the homogenate was used for the assay. In a separate plate, pre-mixed cocktail solutions containing different concentrations of glucose were aliquotted, then transferred to the wells containing liver homogenate. This was done over glucose concentrations 0–20 mmol/l. Glucose 6-phosphate formed by glucokinase was measured by the formation of NADPH in the presence of G6PDH, as previously described .
Urinary BPA concentration was measured using a super-sensitive ELISA (Biosense Laboratories; Bergen, Norway).
The average mouse weight was 29.2 g and the average water intake was 8 ml/day. For the 2-week exposure protocol, BPA was dissolved in water to 1.75 mM resulting in an average daily exposure of 50 µg/kg/day. One unit of glucokinase activity is defined as the amount of the enzyme required to produce 1 µmol of G-6-P in 1 minute. Reported data are for specific activity of the enzyme (activity/protein concentration).
Data are presented as mean ± SEM. Glucokinase activity over a range of glucose concentrations were examined for best fit prior to analysis (GraphPad Prism 5; La Jolla, CA). An overall treatment effect in BPA-exposed vs. non-exposed mice was estimated by repeated measures (two-way ANOVA). Differences in glucokinase activity between groups for a given glucose concentration were compared using two-sample Student’s t-tests. Negative values for glucokinase activity were considered zero. An alpha level of 0.05 was used throughout the study.
Acute BPA Exposure
Hepatic glucokinase kinetics for the BPA-treated and control mice are described in Table 1. Glucokinase activity was significantly lower at 5 mmol glucose for the BPA exposed animals (p = 0.029), as well as at 10 mmol/l (p = 0.002) and 20 mmol/l (p = 0.002) glucose. As depicted in Figure 1A, 2-hour BPA exposure largely abolished glucokinase activity over the range of physiologic glucose concentrations tested (overall treatment effect p<0.001) through a decline in the Vmax and an increase in the enzyme’s Hill coefficient.
Figure 1. Glucokinase specific activity at different glucose concentrations (range 0–20 mmol/l) in mice 2 hours after acute BPA exposure (A; overall treatment effect p<0.001) or after 2 weeks chronic BPA exposure (B; overall treatment effect p = 0.003).doi:10.1371/journal.pone.0069991.g001
Table 1. Glucokinase (GCK) kinetics in the control and BPA groups after acute and chronic BPA exposure.doi:10.1371/journal.pone.0069991.t001
Chronic BPA Exposure
Mice treated for 2 weeks with BPA had higher concentration of BPA in their urine compared to control animals (p = 0.02; Table 1), confirming their exposure. After 2 weeks of dietary BPA intake, hepatic glucokinase activity was significantly reduced over the range of glucose concentrations tested (overall treatment effect p = 0.003; Figure 1B) with particular divergence at 20 mmol/l (p = 0.047) and altered enzyme kinetics.
The rise in human exposure to bisphenol A [2,2-bis(p-hydroxylphenyl)propane] (BPA) has largely mirrored the rise in incident type 2 diabetes. BPA is a chemical used widely in the production of epoxy resins and polycarbonate plastics. Because of its pervasive use in the lining of food and beverage containers, medical supplies and dental sealants, human exposure has been deemed virtually ubiquitous. Population biomonitoring studies estimate the current adult exposure to BPA ≤1 µg/kg/day , well below the purported “safe dose” of 50 µg/kg/day set by the Environmental Protection Agency in the 1980’s. Yet few assertions in medicine today are as controversial. A recent review of the >80 biomonitoring studies cast serious doubt on whether past estimates are accurate or whether the acceptable level of exposure ensures any degree of safety . Because of BPA’s known anti-estrogenic effects  and the known effect of estrogen to stimulate glucokinase  – the body’s glucose sensor – we examined the direct effect of BPA on hepatic glucokinase activity. Major findings from this study demonstrate that both acute and chronic BPA exposure – at a dose deemed safe in humans –impair hepatic glucokinase activity and function. These results provide a potential link as to how BPA exposure may increase risk for diabetes and have alarming implications for public health.
To explore the association between BPA exposure and increased risk for diabetes, we examined the effect of acute ingestion of BPA on glucose sensing. Orally administered BPA is metabolized by glucuronidation during first pass metabolism in the liver, with its peak seen at 2 hours, a biological half-life of approximately 6 hours and nearly complete elimination in 24 hours . Based on the above BPA absorption parameters established in humans, we administered the maximum “safe dose” (50 µg/kg) dissolved in water to mice expecting maximum biologic effects 1–3 hours post-ingestion. Results from the current study demonstrate nearly complete suppression in overall hepatic glucokinase activity and significant alteration in intrinsic enzyme kinetics in mice 2 hours after ingestion of BPA. Although human exposure is unlikely to occur at this level in a single dose, these data are the first to contend that this dose is not safe and has physiological ramifications relevant to the development of diabetes, at least in mice.
Due to possible exposure through dermal absorption, inhalation and ingestion, the precise pharmacokinetics of chronic BPA exposure are less clear . What is clear is that BPA exposure is virtually ubiquitous and constant. A recent survey identified BPA in 63 of 105 food samples, including fresh turkey, canned green beans, and infant formula , suggesting that human exposure is frequent, but also at low levels, rather than in large boluses. Ad libitum water (spiked with 1.75 mmol BPA) intake by our mice over 14 days also demonstrated a significant negative effect on overall hepatic glucokinase activity and function, albeit less pronounced than the effect of the acute BPA exposure. Importantly, however, these experiments capture the influence of low and intermittent exposure of BPA on hepatic glucose sensing, likely more representative of its true effects in the human population. Furthermore, mathematical models  would contend that impaired glucose sensing to the degree observed in the 2-hour and 2-week experiments could lead to clinical diabetes .
Several limitations of the current study are worth noting in its interpretation. First, experiments were conducted exclusively in mice, hence results may not be reproducible in humans. Second, all mice were male, hence we cannot comment on the impact of BPA exposure in female mice. Lastly, the effect of BPA exposure on glucokinase activity was presumed through the action of BPA on the estrogen receptor, however, this was not specifically investigated in this brief report.
In conclusion, major findings from this study demonstrate that both acute and chronic BPA exposure – at a dose deemed safe in humans –impair hepatic glucokinase activity and function in mice. These results provide a plausible link between BPA exposure and risk for diabetes. Future research is needed to determine whether BPA impairs glucose sensing in humans and if it can be restored through BPA avoidance. Such research could have a significant impact on food packaging, dietary selections and legislation relevant to public health.
Conceived and designed the experiments: LP CM KF BCB. Performed the experiments: CM AAK JH BCB. Analyzed the data: LP KF. Contributed reagents/materials/analysis tools: CM AAK JH BCB. Wrote the paper: LP KF BCB. Sent comments and approved manuscript: CM AAK JH.
- 1. Baillie-Hamilton PF (2002) Chemical toxins: a hypothesis to explain the global obesity epidemic. Journal of alternative and complementary medicine 8: 185–192. doi: 10.1089/107555302317371479
- 2. Lang IA, Galloway TS, Scarlett A, Henley WE, Depledge M, et al. (2008) Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA : the journal of the American Medical Association 300: 1303–1310. doi: 10.1001/jama.300.11.1303
- 3. Richter CA, Birnbaum LS, Farabollini F, Newbold RR, Rubin BS, et al. (2007) In vivo effects of bisphenol A in laboratory rodent studies. Reproductive toxicology 24: 199–224. doi: 10.1016/j.reprotox.2007.06.004
- 4. Okada H, Tokunaga T, Liu X, Takayanagi S, Matsushima A, et al. (2008) Direct evidence revealing structural elements essential for the high binding ability of bisphenol A to human estrogen-related receptor-gamma. Environmental health perspectives 116: 32–38. doi: 10.1289/ehp.10587
- 5. Hugo ER, Brandebourg TD, Woo JG, Loftus J, Alexander JW, et al. (2008) Bisphenol A at environmentally relevant doses inhibits adiponectin release from human adipose tissue explants and adipocytes. Environmental health perspectives 116: 1642–1647. doi: 10.1289/ehp.11537
- 6. Alonso-Magdalena P, Ropero AB, Carrera MP, Cederroth CR, Baquie M, et al. (2008) Pancreatic insulin content regulation by the estrogen receptor ER alpha. PLoS One 3: e2069. doi: 10.1371/journal.pone.0002069
- 7. Bindhumol V, Chitra KC, Mathur PP (2003) Bisphenol A induces reactive oxygen species generation in the liver of male rats. Toxicology 188: 117–124. doi: 10.1016/s0300-483x(03)00056-8
- 8. Cabrera-Valladares G, German MS, Matschinsky FM, Wang J, Fernandez-Mejia C (1999) Effect of retinoic acid on glucokinase activity and gene expression and on insulin secretion in primary cultures of pancreatic islets. Endocrinology 140: 3091–3096. doi: 10.1210/endo.140.7.6765
- 9. Cabrera-Valladares G, Matschinsky FM, Wang J, Fernandez-Mejia C (2001) Effect of retinoic acid on glucokinase activity and gene expression in neonatal and adult cultured hepatocytes. Life Sci 68: 2813–2824. doi: 10.1016/s0024-3205(01)01065-7
- 10. Romero-Navarro G, Cabrera-Valladares G, German MS, Matschinsky FM, Velazquez A, et al. (1999) Biotin regulation of pancreatic glucokinase and insulin in primary cultured rat islets and in biotin-deficient rats. Endocrinology 140: 4595–4600. doi: 10.1210/endo.140.10.7084
- 11. Zhang H, Osada K, Sone H, Furukawa Y (1997) Biotin administration improves the impaired glucose tolerance of streptozotocin-induced diabetic Wistar rats. J Nutr Sci Vitaminol (Tokyo) 43: 271–280. doi: 10.3177/jnsv.43.271
- 12. Mukhtar M, Stubbs M, Agius L (1999) Evidence for glucose and sorbitol-induced nuclear export of glucokinase regulatory protein in hepatocytes. FEBS letters 462: 453–458. doi: 10.1016/s0014-5793(99)01580-x
- 13. Alonso-Magdalena P, Morimoto S, Ripoll C, Fuentes E, Nadal A (2006) The estrogenic effect of bisphenol A disrupts pancreatic beta-cell function in vivo and induces insulin resistance. Environmental health perspectives 114: 106–112. doi: 10.1289/ehp.8451
- 14. Soriano S, Alonso-Magdalena P, Garcia-Arevalo M, Novials A, Muhammed SJ, et al. (2012) Rapid insulinotropic action of low doses of bisphenol-A on mouse and human islets of Langerhans: role of estrogen receptor beta. PLoS One 7: e31109. doi: 10.1371/journal.pone.0031109
- 15. Takeuchi T, Tsutsumi O, Ikezuki Y, Takai Y, Taketani Y (2004) Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. Endocrine journal 51: 165–169. doi: 10.1507/endocrj.51.165
- 16. Gould JC, Leonard LS, Maness SC, Wagner BL, Conner K, et al. (1998) Bisphenol A interacts with the estrogen receptor alpha in a distinct manner from estradiol. Molecular and cellular endocrinology 142: 203–214. doi: 10.1016/s0303-7207(98)00084-7
- 17. Ratnasabapathy R, Tom M, Post C (1997) Modulation of the hepatic expression of the estrogen-regulated mRNA stabilizing factor by estrogenic and antiestrogenic nonsteroidal xenobiotics. Biochemical pharmacology 53: 1425–1434. doi: 10.1016/s0006-2952(97)00084-1
- 18. Yoon K, Pellaroni L, Ramamoorthy K, Gaido K, Safe S (2000) Ligand structure-dependent differences in activation of estrogen receptor alpha in human HepG2 liver and U2 osteogenic cancer cell lines. Molecular and cellular endocrinology 162: 211–220. doi: 10.1016/s0303-7207(99)00261-0
- 19. Pakoskey AM, Lesher EC, Scott DB (1965) Hexokinase of Escherichia Coli. Assay of Enzyme Activity and Adaptation to Growth in Various Media. J Gen Microbiol 38: 73–80. doi: 10.1099/00221287-38-1-73
- 20. Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL (2008) Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003–2004. Environmental health perspectives 116: 39–44. doi: 10.1289/ehp.10753
- 21. Vandenberg LN, Chahoud I, Padmanabhan V, Paumgartten FJ, Schoenfelder G (2010) Biomonitoring studies should be used by regulatory agencies to assess human exposure levels and safety of bisphenol A. Environmental health perspectives. 118: 1051–1054. doi: 10.1289/ehp.0901717
- 22. Magnaterra R, Porzio O, Piemonte F, Bertoli A, Sesti G, et al. (1997) The effects of pregnancy steroids on adaptation of beta cells to pregnancy involve the pancreatic glucose sensor glucokinase. The Journal of endocrinology 155: 247–253. doi: 10.1677/joe.0.1550247
- 23. Volkel W, Colnot T, Csanady GA, Filser JG, Dekant W (2002) Metabolism and kinetics of bisphenol a in humans at low doses following oral administration. Chemical research in toxicology 15: 1281–1287. doi: 10.1021/tx025548t
- 24. Ginsberg G, Rice DC (2009) Does rapid metabolism ensure negligible risk from bisphenol A? Environmental health perspectives 117: 1639–1643. doi: 10.1289/ehp.0901010
- 25. Schecter A, Malik N, Haffner D, Smith S, Harris TR, et al. (2010) Bisphenol A (BPA) in U.S. food. Environmental science & technology 44: 9425–9430. doi: 10.1021/es102785d
- 26. Matschinsky FM (2002) Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics. Diabetes 51 Suppl 3S394–404. doi: 10.2337/diabetes.51.2007.s394
- 27. Davis EA, Cuesta-Munoz A, Raoul M, Buettger C, Sweet I, et al. (1999) Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis. Diabetologia 42: 1175–1186. doi: 10.1007/s001250051289